PET/MRI of Primary Sclerosing Cholangitis
Key facts
- Who runs it
- Massachusetts General Hospital
- Where
- Charlestown, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- People taking part
- 10 people, planned
- Starts
- 10 Dec 2026
- Expected to end
- 30 Apr 2029
- Type of study
- Observational
- Treatments tested
- Radiotracer Injection
- Contrast Media, Magnetic Resonance
- Imaging
- Record updated
- 14 October 2026
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Established clinical diagnosis of large duct PSC
- Participants receiving treatment for IBD are allowed if on a stable dose from screening and expected to remain stable for the duration of the study
- Serum AST and ALT concentration ≤ 8 times the upper limit of normal
Who cannot take part
- Subjects whose research-related radiation exposure exceeds current Radiology Department guidelines (i.e., 50 mSv in the prior 12 months)
- Perioperative liver transplantation period
- Other causes of chronic liver disease, including secondary sclerosing cholangitis or viral, metabolic, or alcoholic liver disease, as assessed clinically
- Known or suspected overlapping clinical or histologic diagnosis of autoimmune hepatitis
- Subjects with electrical implants, such as cardiac pacemakers or perfusion pumps
- Subjects with ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, prosthetic heart valves that are not compatible with the gradient maps of our scanners, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or steel implants ferromagnetic objects such as jewelry or metal clips in clothing
- Subjects with more significant than average potential for cardiac arrest
- Subjects with a history of major head trauma (i.e., multiple concussions, traumatic brain injury)
- Subjects with a history of bleeding disorders
- A history of acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2
- A history of systemic lupus, multiple myeloma, nephrogenic systemic fibrosis, or other comorbidities resulting in chronic kidney disease stage IV or higher
- Subjects who anticipate being pregnant or breastfeeding (a negative STAT quantitative serum hCG pregnancy test is required on the day of the scan before the subject can participate)
- Subjects less than 18 years of age or greater than 85 years of age
- Subjects with claustrophobic reactions
- Subjects unable to lie comfortably on a bed inside the PET/MRI bore as assessed by physical examination and medical history (e.g., back pain, arthritis)
- Subjects under the direct supervision of the principal investigator
- Subjects with a body weight of > 300 lbs (operational weight limit of the PET/MRI table) or BMI >33 kg/m2 (the Athinoula A. Martinos Center standard procedure to avoid claustrophobia or mechanical impossibility of fitting the subject into the scanner bore, which is less than 60 cm wide)
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Where in United States
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical SchoolCharlestown, United StatesContact: Onofrio Catalano, MD, Ph.DNot yet recruiting
About the trial
What the trial wants to find out
This study aims to use positron emission tomography (PET)/magnetic resonance imaging (MRI) to diagnose and quantify PSC-related biliary tract fibrosis and to improve upon the currently available non-invasive diagnostic capabilities by investigating the ability of combined PET/MRI to detect and quantify fibrosis using a novel collagen-binding radiotracer. Specifically, the investigators will be comparing [68Ga]CBP8- and [18F]-FAPI-74 PET/MRI to a liver transient elastography scan in the diagnosis of biliary tree fibrosis.
The group in the trial
- PSC
Population will be consecutive patients with PSC, who will be referred to us by the MGB-affiliated hepatologists.
Treatment: Radiotracer Injection, Contrast Media, Magnetic Resonance, and Imaging
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- PET/MRI Evaluation in Patients With Primary Sclerosing Cholangitis Using Intercellular Matrix Radiopharmaceuticals
- Criteria questions
- Built from NCT06252610, who can take part
- Record updated
- 14 October 2026